Effect of regorafenib combined with acupuncture and moxibustion vs regorafenib as third-line treatment in patients with metastatic colorectal cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100004755

Enrollment

Unknown

Registered

2021-04-19

Start date

2021-05-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Interventions

Control Group:Regofinib + best supportive care

Intervention Group:Acupuncture + regofinib + best supportive treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Histologically confirmed colorectal cancer; 3. Complete second-line chemotherapy and molecular targeted therapy; 4. Eastern Cooperative Oncology Group(ECOG) performance status 0-1; 5. At least one measurable lesion.

Exclusion criteria

Exclusion criteria: 1. A past history of checkpoint inhibitor-based immunotherapies; 2. Severe cardiovascular, hepatic, or renal disease; 3. Current infection; 4. Acupuncture or moxibustion treatment within 1 month before the trial; 5. Autoimmune disease.

Design outcomes

Primary

Measure	Time frame
GATA3 / IL-4;T-bet /I FN-?;CEA / Ca199;	—

Secondary

Measure	Time frame
Cholinesterase;C-reactive protein, CRP;	—

Countries

China

Contacts

Public ContactZhang Yongjie

Huai'an Second People's Hospital

zhangyj0818@126.com+86 18762096966

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026